NephroNET

We are dedicated to providing resources to patients, practicing clinicians, and all individuals concerned w/ improving the care of patients with kidney disease.

[NephroNET @NephroNet]

In the APPEAR-C3G trial, oral iptacopan achieved a 35% relative reduction in proteinuria vs placebo at 6 months and was well tolerated on top of standard care. A major advance for targeted complement inhibition in C3G.
#C3G #RareDisease #ClinicalTrials
https://t.co/LdNMl5FbBZ

[NephroNET @NephroNet]

FACT trial results in fibrillary glomerulopathy
In DNA-JB9+ FGN, Acthar® Gel significantly reduced proteinuria at 6 & 12 months. Adding tacrolimus did not improve outcomes. Supports Acthar as an effective antiproteinuric option in this rare disease.
https://t.co/Q0t9NAUisW

[NephroNET @NephroNet]

Proteinuria remission = kidney protection in IgAN
Post hoc PROTECT analysis: Patients achieving complete proteinuria remission (<0.3 g/day) had slower eGFR decline, fewer kidney events, and better outcomes vs non-responders.
#IgAN #Nephrology
https://t.co/f9kN9aRsRH

[NephroNET @NephroNet]

New systematic review & meta-analysis shows kidney transplant reduces mortality, CV events, and infections vs dialysis in lupus nephritis–related ESKD. Dialysis modality didn’t affect survival.
#LupusNephritis #ESKD #Rheumatology
https://t.co/odxWE2D6Nq

[NephroNET @NephroNet]

Post hoc analysis of AURORA 1 shows voclosporin did not increase kidney injury or pro-fibrotic biomarkers vs standard therapy alone even in patients with eGFR decline. Reassuring safety signal in LN.
https://t.co/iGnLq1KlAX
#LupusNephritis #Nephrology #Voclosporin

[NephroNET @NephroNet]

What an incredible week at #ASN2026! Thank you to everyone who stopped by Booth #361. We're heading home with new connections, fresh ideas, and excitement for what's ahead!

✈️ Denver, you've been amazing! Atlanta, here we come!

#NephroNet #KidneyResearch

[NephroNET @NephroNet]

How's everyone enjoying ASN 2026 so far? 🙌 We've loved the energy, conversations, and opportunities to connect with so many incredible people. If we haven't crossed paths yet, there's still time!
Come by and visit us at Booth #361!

#ASN2026 #NephroNet #KidneyCare

[NephroNET @NephroNet]

ASN 2026 is officially underway, and we're ready for an exciting week!
📍 Find us at Booth #361!

Let's connect, collaborate, and keep moving kidney research forward!

#ASN2026 #NephroNet #KidneyResearch #ClinicalTrials

[NephroNET @NephroNet]

The NephroNet team is officially on our way to ASN 2026!

We're looking forward to seeing our friends, colleagues, and research partners for an incredible week of connecting, collaborating, and advancing kidney care.

📍 See you at Booth #361!

#ASN2026 #NephroNet #DenverBound

[NephroNET @NephroNet]

A new review proposes a paradigm shift—focusing on nephron preservation and lifetime prevention, not just short-term biomarkers. A multifaceted approach targeting both IgAN-specific mechanisms and maladaptive kidney responses may redefine management.
https://t.co/SKJx0wGT7w

[NephroNET @NephroNet]

We're just days away from ASN 2026, and we're looking forward to a week filled with great conversations, meaningful connections, and exciting advances in kidney care.

Make sure Booth #361 is on your list of stops. We can't wait to see everyone!

#ASN2026 #NephroNet #KidneyCare

[NephroNET @NephroNet]

💜 Lupus nephritis affects up to 60% of SLE patients and remains a leading cause of kidney failure.
New therapies target immune pathways — but early diagnosis & coordinated care are key to preserving kidney function.
#Lupus #Nephrology #AutoimmuneDisease
https://t.co/1i7pjQayCp

[NephroNET @NephroNet]

ASN 2026 is almost here! What are YOU most excited about — groundbreaking research, new treatments, clinical trial updates, or reconnecting with colleagues?

We'd love to hear what you're looking forward to most! Drop a comment below.

#ASN2026 #NephroNet #KidneyResearch

[NephroNET @NephroNet]

We're excited to be heading to ASN 2026 and can't wait to reconnect with familiar faces, make new connections, and share what we've been working on!

📍 Stop by Booth #361 to say hello. We'd love to see you!

#ASN2026 #NephroNet #KidneyResearch #Denver2026

[NephroNET @NephroNet]

🧠 Nanoparticles that “teach” immune cells tolerance.
Cationic lipid–modified PEG-PLGA nanoparticles (CLAN) deliver dual siRNAs to dendritic cells, reducing T-cell inflammation in MS models.
💡 New path to reprogram immunity.
#Nanomedicine #Immunotherapy
https://t.co/5vMYEHqmWs

[NephroNET @NephroNet]

In Jakarta, 1 in 7 adults with diabetes or hypertension already has CKD.
📉 eGFR declines ~4.7 mL/min/year.
⚠️ 49% face moderate–very high risk despite “normal” kidney function.
Screening early saves kidneys.
#CKD #Nephrology #Diabetes #Hypertension
https://t.co/MaP7xfz3u8

[NephroNET @NephroNet]

⚠️ In Type 1 diabetes, overweight doubles CAD risk.
📊 J-DREAMS registry: 8.9% CAD in overweight vs. 3.4% in non-overweight adults.
Early weight control = stronger heart & kidney protection.
#Type1Diabetes #CardiovascularHealth #Obesity #DiabetesResearch
https://t.co/ojKlqSA71F

[NephroNET @NephroNet]

In Type 2 diabetes, 🩸
⬇️ Adropin levels + ⬆️ miR-21 expression = endothelial dysfunction.
These markers may predict vascular complications early — from nephropathy to neuropathy.
#Diabetes #CardiometabolicHealth #EndothelialFunction #miR21
https://t.co/sQyCt4Wpf0

[NephroNET @NephroNet]

Higher Triglyceride-Glucose (TyG) index = higher kidney risk ⚠️
In 9,661 adults, those in the top TyG quartile had a 75% higher chance of reduced eGFR.
💡 Lipid + glucose imbalance may predict kidney decline early.
#Nephrology #CKD #TyGIndex #PublicHealth
https://t.co/4pvzdQKPVd

[NephroNET @NephroNet]

Blocking BAFF reduced total antibodies but didn’t stop abnormal IgA production in a murine IgAN model.
🧬 Suggests BAFF isn’t central to generating nephritogenic IgA.
➡️ IgAN therapy may require more targeted immune modulation.
#IgAN #Nephrology
https://t.co/PgkcJSXUI1